Head-to-head · WeighScore
Alinwell vs RX Bella
By GLP-1 ScorecardUpdated
Score comparison
RX Bella has the higher recorded score — 67.8/100 to 61.2/100.
RX Bella grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Four routes priced from a floor on the homepage, a hero quoting the cheapest of the four, and treatment pages that carry no price at all.
Before you choose
Before comparing the headline prices, the Alinwell review and the RX Bella review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, Alinwell vs Trimi and Clume Health vs RX Bella compare each of them with another graded program, and the list of alternatives to Alinwell ranks the programs closest to Alinwell on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the Lttl review covers one graded close to these two, at 63.5/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Alinwell | RX Bella |
|---|---|---|
| WeighScore | 61.2/100 | 67.8/100 |
| Grade | C | C |
| Site position | #325 | #171 |
| Semaglutide | From $139/mo; confirm plan length and renewal | From $249/mo (a floor, not a rate) |
| Tirzepatide | From $166/mo; confirm plan length and renewal | From $299/mo (a floor, not a rate) |
| Coverage | All 50 states advertised; confirm plan eligibility | Nationwide telehealth, claimed |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Yes |
Strengths
- Names both treatments and advertises service across all 50 states
- Terms describe how bundled subscriptions account for prescription and consultation charges when applicable
What to consider
- Starting figures leave the selected charge and renewal unconfirmed
- Terms say 48 hours before the charge while treatment FAQs say 30 days’ notice
- The public offer does not confirm the pharmacy assigned to a specific order
Strengths
- All four programs — microdose, oral, semaglutide injection, tirzepatide injection — carry a figure on the homepage before any intake
- Nothing in the catalog is struck through: no invented "was" price and no expiring offer
- "$0 if you're not approved" is stated plainly and repeatedly
- The online provider visit, prescription, delivery and ongoing check-ins are stated as included
What to consider
- The hero's "from $199/mo" is the microdose; the tirzepatide program is $299
- Every figure is a floor, no dose ladder is published, and the eight-screen intake reaches an email gate without showing a price
- Its own treatment pages carry no dollar figure and read "AVAILABLE BY CONSULTATION"
- No lab or monitoring requirement is published
- The compounding pharmacies are never named and the footer names no company
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.